These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32816220)

  • 21. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
    Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.
    Sanchez RI; Yee KL; Fan L; Cislak D; Martell M; Jordan HR; Iwamoto M; Khalilieh S
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):107-114. PubMed ID: 30973682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
    Lam E; Schaefer J; Zheng R; Zhan T; Kraft WK
    Clin Transl Sci; 2020 Nov; 13(6):1244-1250. PubMed ID: 32407548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Talwani R; Temesgen Z
    Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
    Schürmann D; Sobotha C; Gilmartin J; Robberechts M; De Lepeleire I; Yee KL; Guo Y; Liu R; Wagner F; Wagner JA; Butterton JR; Anderson MS
    AIDS; 2016 Jan; 30(1):57-63. PubMed ID: 26372481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic analysis of doravirine in real-world people with HIV.
    Thoueille P; Delarive L; Cavassini M; Buclin T; Decosterd LA; Marzolini C; Girardin FR; Guidi M;
    Br J Clin Pharmacol; 2024 Apr; 90(4):1058-1065. PubMed ID: 37994177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
    Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
    Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.
    Khalilieh SG; Yee KL; Sanchez RI; Liu R; Fan L; Martell M; Jordan H; Iwamoto M
    J Clin Pharmacol; 2018 Aug; 58(8):1044-1052. PubMed ID: 29723418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.
    Yee KL; Mittal S; Fan L; Triantafyllou I; Dockendorf MF; Fackler PH; Stoch SA; Khalilieh SG; Iwamoto M
    J Clin Pharm Ther; 2020 Oct; 45(5):1098-1105. PubMed ID: 32501541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
    Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
    Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.
    Anderson MS; Gilmartin J; Fan L; Yee KL; Kraft WK; Triantafyllou I; Reitmann C; Guo Y; Liu R; Iwamoto M
    Antivir Ther; 2019; 24(6):443-450. PubMed ID: 31433304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational Design of Doravirine: From Bench to Patients.
    Hwang C; Lai MT; Hazuda D
    ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
    Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; Klopfer SO; Grandhi A; Eves K; Hepler D; Robertson MN; Hwang C; Hanna GJ; Correll T
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):68-72. PubMed ID: 35972855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL).
    O'Halloran C; Gilleece Y; Leung S; Canuto V; McAlpine C; Ross S; Norcross C; Gaffney S; Siani N; Hickey W; Moore A; Rajkovic-Hooley O; Milinkovic A
    Int J STD AIDS; 2024 Mar; 35(3):206-216. PubMed ID: 37970812
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
    Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
    Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.